Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenylpropanolamine→

Phenylpropanolamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14838-15-4
Molecular formula
C9H13NO
Molecular weight
151.21 g/mol
Drug class
Sympathomimetic aminepredominantly indirect adrenergic agonist and nasal decongestant
Mechanism of action
Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.
Indications / reported uses
  • Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
  • It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.

Sources: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Term=%22Phenylpropanolamine%22%5BMeSH+Terms%5D · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D010665 · https://pubchem.ncbi.nlm.nih.gov/compound/10297

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Sympathomimetic amine; predominantly indirect adrenergic agonist and nasal decongestant

Mechanism of action

Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.

General use cases

  • Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
  • It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Phenylpropanolamine Environmental Risk Assessment (ERA) (the Phenylpropanolamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.